FSCN1 and neoplasm: One of the initial fascin inhibitor hits was optimized through medicinal chemistry, and the improved fascin inhibitors blocked the actin-binding and actin-bundling activities of fascin, as well as tumor cell migration, invasion and metastasis [19].